{"id":"placebo-to-match-danazol","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo-to-match formulations are inert preparations engineered to be indistinguishable from the active drug in terms of appearance, taste, smell, and packaging to maintain blinding in randomized controlled trials. In this case, the placebo is formulated to match danazol, an androgenic steroid, allowing researchers to compare the efficacy and safety of danazol against an inactive control while preventing bias from participants or investigators knowing treatment assignment.","oneSentence":"This is a placebo formulation designed to match the appearance and administration of danazol for use as a control in clinical trials.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:28:47.287Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 clinical trial comparing danazol efficacy"}]},"trialDetails":[{"nctId":"NCT04638517","phase":"PHASE2","title":"The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis","status":"TERMINATED","sponsor":"The University of Queensland","startDate":"2021-09-07","conditions":"Pulmonary Fibrosis, Telomere Shortening, Telomere Disease","enrollment":29},{"nctId":"NCT04173494","phase":"PHASE3","title":"A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)","status":"COMPLETED","sponsor":"Sierra Oncology LLC - a GSK company","startDate":"2020-02-07","conditions":"Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis","enrollment":195}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to match danazol","genericName":"Placebo to match danazol","companyName":"Sierra Oncology LLC - a GSK company","companyId":"sierra-oncology-llc-a-gsk-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo formulation designed to match the appearance and administration of danazol for use as a control in clinical trials. Used for Control arm in phase 3 clinical trial comparing danazol efficacy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}